Roy S. Herbst, MD, PhD

Articles

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Dr Herbst on Notable Research Avenues for Patients With Unmutated NSCLC

October 28th 2024

Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

July 24th 2024

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC

June 4th 2023

Roy S. Herbst, MD, PhD, discusses findings from the overall survival analysis of the phase 3 ADAURA trial of adjuvant osimertinib in patients with stage IB to IIIA resected non–small cell lung cancer harboring EGFR mutations.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 2nd 2023

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Dr. Herbst on the Evolution of Targeted Therapies in NSCLC

April 5th 2022

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 2nd 2020

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22nd 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26th 2019

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC

October 25th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Dr. Herbst Discusses Challenges With Immunotherapy in NSCLC

August 27th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Dr. Herbst on Key Immunotherapy Findings in NSCLC

August 10th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

July 28th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Dr. Herbst on the Bevacizumab Biosimilar in Lung Cancer

July 11th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.